# BEAM — slm-full-gpu

## Metadata

ticker: BEAM
arm: slm-full-gpu
judge_prompt_version: v2
context_sha256: 2a1045e619ed4a3425327b9cdf635bfea675d43c5ec165c9d971f2f2a3955926
slm_endpoint: slm-gpu
slm_url: http://132.145.161.150:30880
slm_served_name: qwen3.6-35b-a3b-q4km
slm_artifact: ggml-org/Qwen3.6-35B-A3B-GGUF@baec3ebee244827cda0f4557eafa8b28f7545fa6:Qwen3.6-35B-A3B-Q4_K_M.gguf sha256:671e47e0ec53c665d048b98c3ecbfd5236b5ca9c3e02ed19fc8f81f7b85140c7
slm_build: b11347-5fc4f3c8c
slm_model_path: /models/Qwen3.6-35B-A3B-Q4_K_M.gguf
slm_model_ftype: Q4_K - Medium
slm_total_slots: 4
slm_n_ctx: 32768
slm_n_params: 34660610688
slm_model_size_bytes: 20408576512
slm_thinking: off
slm_sampling: {"planner": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "rag": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 2048, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "react": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "section": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 768, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "synthesis": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 4096, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.2, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}}
llm_calls: 7
llm_endpoints: slm-gpu
llm_by_site: {"rag:highlights": {"calls": 1, "completion_tokens": 647, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 20.227, "latency_s_total": 20.227, "parse_failure": 0, "prompt_tokens": 3093, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "rag:risks": {"calls": 1, "completion_tokens": 451, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 14.891, "latency_s_total": 14.891, "parse_failure": 0, "prompt_tokens": 2340, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:financial_health": {"calls": 1, "completion_tokens": 141, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 11.54, "latency_s_total": 11.54, "parse_failure": 0, "prompt_tokens": 699, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:recent_developments": {"calls": 1, "completion_tokens": 168, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 11.043, "latency_s_total": 11.043, "parse_failure": 0, "prompt_tokens": 693, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:risk_factors": {"calls": 1, "completion_tokens": 194, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 16.642, "latency_s_total": 16.642, "parse_failure": 0, "prompt_tokens": 523, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:sec_filing_highlights": {"calls": 1, "completion_tokens": 150, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 15.203, "latency_s_total": 15.203, "parse_failure": 0, "prompt_tokens": 727, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "synthesis": {"calls": 1, "completion_tokens": 948, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 30.346, "latency_s_total": 30.346, "parse_failure": 0, "prompt_tokens": 1684, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}}

## Retrieved source context

STOCK DATA:
{
  "ticker": "BEAM",
  "company_name": "Beam Therapeutics Inc.",
  "current_price": 24.77,
  "currency": "USD",
  "market_cap": 2558435584.0,
  "forward_pe": -5.2242284,
  "week_52_high": 38.26,
  "week_52_low": 20.23,
  "financial_currency": "USD",
  "revenue": 156035008.0,
  "net_income": -86520000.0,
  "profit_margin_pct": -55.45,
  "dividend_yield": 0.0,
  "sector": "Healthcare",
  "industry": "Biotechnology"
}

NEWS ARTICLES:
[
  {
    "title": null,
    "source": null,
    "published_at": null,
    "description": null
  }
]

SEC FILING SUMMARIES:
{
  "10-K": {
    "form_type": "10-K",
    "filing_date": "2026-02-24",
    "summary": "Item 1A. Risk Factors. You should carefully consider the risks and uncertainties described below together with all of the other information contained in this Annual Report on Form 10-K, including our consolidated financial statements and related notes appearing at the end of this Annual Report on Form 10-K, in evaluating our company. If any of the events or developments described below were to occur, our business, prospects, operating results and financial condition could suffer materially, and the trading price of our common stock could decline. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business. Risks related to our fina"
  },
  "10-Q": {
    "form_type": "10-Q",
    "filing_date": "2026-08-04",
    "summary": "Item 1A. Risk Fa ctors. In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in the sections titled sections titled \u201cRisk Factors Summary\u201d and \u201cItem 1A. Risk Factors\u201d in the 2025 Form 10-K, which could materially affect our business, financial condition or future results. The risk factors disclosure in the 2025 Form 10-K is qualified by the information in this Quarterly Report on Form 10-Q. The risks described in the 2025 Form 10\u2013K are not our only risks. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results. The risk factors set forth below represent new risk factors o"
  }
}

RAG — SEC HIGHLIGHTS:
[From Pinecone cache] Based on the provided risk factors from the SEC EDGAR filing for BEAM, here are the key takeaways regarding the company's financial position, operational status, and future outlook:

**Financial Performance and Capital Needs**
*   **Significant Losses:** The company has incurred substantial operating losses since inception, with net losses of $80.0 million, $376.7 million, and $132.5 million for the years ended December 31, 2025, 2024, and 2023, respectively. As of December 31, 2025, the accumulated deficit stood at $1.6 billion.
*   **Need for Additional Funding:** BEAM expects to incur significant expenses and increasing operating losses for the foreseeable future. The company requires substantial additional funding to support research and development, clinical trials, and potential commercialization efforts.
*   **Current Liquidity:** As of December 31, 2025, the company held $1.2 billion in cash, cash equivalents, and marketable securities, which management believes is sufficient to fund operations and capital expenditures for at least the next 12 months. However, the company has no committed sources of additional capital other than a credit facility with Sixth Street Lending Partners.
*   **Dilution and Restrictions:** Raising additional capital through equity or debt may result in dilution to existing stockholders or impose restrictive covenants. Failure to raise capital on acceptable terms could force the company to delay, reduce, or eliminate research programs.

**Operational Status and Product Development**
*   **Early-Stage Development:** BEAM is an early-stage company founded in 2017. It has not yet completed any pivotal clinical trials, obtained marketing approvals, or demonstrated the ability to manufacture commercial-scale medicines or conduct successful sales and marketing activities.
*   **High Risk of Failure:** Many product development programs are in early clinical, preclinical, or research stages, carrying a high risk of failure. The company has not yet achieved profitability and may never do so.
*   **Portfolio Restructuring:** In October 2023, the company announced a portfolio repriorization and strategic restructuring, which included cost-reduction initiatives that led to the pausing or elimination of certain pipeline programs.

**Future Outlook and Risks**
*   **Uncertain Path to Profitability:** The company anticipates that expenses will increase substantially as it advances clinical trials, expands research programs, and seeks marketing approvals. It is unable to predict when or if it will become profitable.
*   **Commercialization Challenges:** Even if product candidates receive approval, there is no guarantee of commercial success. The company may need to establish its own sales, marketing, and distribution infrastructure or rely on collaborators, both of which involve significant costs and risks.
*   **Short Operating History:** With a limited operating history in the rapidly evolving base editing and gene editing field, it is difficult to evaluate the company’s technology, industry position, or future viability. Predictions regarding future success are subject to significant uncertainty.

RAG — RISK FACTORS:
[From Pinecone cache] The primary risk factors disclosed include:

*   **Financial Losses and Need for Capital:** The company has incurred significant operating losses since inception, with net losses of $80.0 million, $376.7 million, and $132.5 million for the years ended December 31, 2025, 2024, and 2023, respectively. As of December 31, 2025, the accumulated deficit was $1.6 billion. The company expects to incur significant expenses and increasing operating losses for the foreseeable future and may never achieve profitability.
*   **Need for Additional Funding:** Substantial additional funding is required to continue operations, expand clinical trials, and seek marketing approvals. If capital cannot be raised when needed or on attractive terms, the company may be forced to delay, reduce, or eliminate research and product development programs or commercialization efforts.
*   **Lack of Commercial History and Product Approval:** The company has not completed any pivotal clinical trials, obtained marketing approvals, manufactured a commercial-scale medicine, or established sales and marketing infrastructure. It has not demonstrated an ability to successfully commercialize a medicine.
*   **Limited Operating History:** The company has a short operating history in the rapidly evolving base editing and gene editing fields, making it difficult to evaluate its technology, industry, or predict future performance.
*   **Execution Risks:** Success requires completing challenging activities such as identifying product candidates, conducting preclinical and clinical trials, obtaining regulatory approval, and manufacturing and marketing medicines. Failure in any of these areas could materially harm the business.
*   **Dependence on Collaborations and Licenses:** The company relies on license agreements and collaborations. Failure to meet payment or other obligations under these agreements could lead to their termination. Additionally, the company faces risks related to the costs of acquiring licenses, maintaining intellectual property, and paying success liabilities to institutions like Harvard and the Broad Institute.
*   **Past Restructuring:** The company has previously delayed, reduced, or eliminated research programs to decrease expenses, such as through the portfolio reprioritization and strategic restructuring announced in October 2023.

## Pre-written sections (judge input)

### Financial Health

Beam Therapeutics Inc. (BEAM) currently trades at $24.77 with a market capitalization of approximately $2.56 billion. The company reported revenue of $156.04 million, but continues to operate with a negative net income of $86.52 million, resulting in a profit margin of -55.45%. Consequently, the forward P/E ratio is negative, reflecting ongoing losses rather than profitability. This financial profile indicates a pre-profit biotechnology stage, where valuation is driven by future pipeline potential rather than current earnings. Investors should note the inherent risk associated with sustained operational losses and the absence of dividend yields.

### Recent Developments

Beam Therapeutics Inc. (BEAM) is currently trading at $24.77, reflecting a market capitalization of approximately $2.56 billion despite reporting a net loss of $86.5 million and a negative profit margin of 55.45%. The company’s forward P/E ratio remains negative at -5.22, underscoring ongoing profitability challenges within its biotechnology operations. While no specific recent news events are currently reported, the upcoming 10-K filing scheduled for February 24, 2026, will be critical for investors to assess updated risk factors and financial health. Consequently, shareholders should closely monitor the company's path toward commercial viability and potential catalysts that could drive revenue growth beyond its current $156 million baseline.

### SEC Filing Highlights
Beam Therapeutics reported a net loss of $80.0 million for the year ended December 31, 2025, bringing its accumulated deficit to $1.6 billion as it continues to incur substantial operating expenses. Despite these losses, the company held $1.2 billion in cash and marketable securities, which management believes is sufficient to fund operations for at least the next 12 months. BEAM remains an early-stage entity with no commercial products or marketing approvals, relying on significant additional funding to support ongoing research and clinical trials. The company recently executed a strategic portfolio restructuring, pausing or eliminating certain programs to reduce costs while navigating the high risks inherent in its base editing technology.

### Risk Factors

*   **Sustained Financial Losses and Capital Dependency:** The company has incurred significant operating losses (accumulated deficit of $1.6 billion as of Dec 2025) and expects to continue losing money; it requires substantial additional funding to sustain operations, and failure to raise capital on attractive terms could force the delay or elimination of development programs.
*   **Pre-Commercial Stage and Execution Risks:** BEAM has no commercial history, has not completed pivotal trials, and lacks a manufacturing or sales infrastructure; success depends on executing complex, high-risk activities like clinical trials and regulatory approvals, any of which could fail and materially harm the business.
*   **Limited Operating History and Collaboration Dependence:** The company has a short track record in the rapidly evolving gene editing field, making performance prediction difficult, and relies heavily on third-party licenses and collaborations where failure to meet obligations could lead to termination or significant financial liabilities.

## Audited (Exec Summary + Outlook)

### Executive Summary
Beam Therapeutics Inc. (BEAM) is a pre-profit biotechnology company specializing in base editing technology, currently trading with a market capitalization of approximately $2.56 billion despite reporting a negative profit margin of -55.45%. The stock is notable for its substantial cash reserves of $1.2 billion, which provide a runway for operations, even as the company navigates a strategic portfolio restructuring to reduce costs amid sustained operational losses. The single most important near-term variable shaping the outcome is the execution of this restructuring and the subsequent progress of its remaining pipeline programs toward commercial viability.

### Outlook
The directional outlook for Beam Therapeutics is cautiously constructive, supported by a strong balance sheet that mitigates immediate dilution risk, but tempered by the inherent execution risks of a pre-commercial biotech firm. Investors should monitor the success of the recent portfolio restructuring in reducing burn rates and the clinical progress of the remaining base editing programs, as these will determine whether the company can transition from a cost-center to a value-generating entity. The thesis would be strengthened by clear milestones in regulatory pathways or successful partnership renewals, while it would be weakened by further program cancellations or signs that the remaining cash runway is insufficient to reach meaningful commercial inflection points without additional capital raises.

---
*This brief is for informational purposes only and does not constitute financial advice.*

## Judge findings

I will now systematically identify every specific quantitative figure, price target, threshold, ratio, metric, percentage, named product milestone, or forward-looking number in the **Executive Summary** and **Outlook** sections, then evaluate each against the source data.

---

**EXECUTIVE SUMMARY**

---

CLAIM: "market capitalization of approximately $2.56 billion"
LABEL: SUPPORTED
REASON: The raw source data lists market_cap as $2,558,435,584.0, which rounds to approximately $2.56 billion, consistent with the pre-written Financial Health and Recent Developments sections.

---

CLAIM: "negative profit margin of -55.45%"
LABEL: SUPPORTED
REASON: The raw source data explicitly states profit_margin_pct as -55.45, and this figure appears verbatim in the pre-written Financial Health and Recent Developments sections.

---

CLAIM: "cash reserves of $1.2 billion"
LABEL: SUPPORTED
REASON: The SEC Highlights (RAG) and SEC Filing Highlights pre-written section both explicitly state the company held $1.2 billion in cash, cash equivalents, and marketable securities as of December 31, 2025.

---

**OUTLOOK**

The Outlook section contains no specific quantitative figures, price targets, thresholds, ratios, metrics, percentages, named product milestones, or forward-looking numbers. All statements are qualitative and directional (e.g., "cautiously constructive," "mitigates immediate dilution risk," "clear milestones," "further program cancellations"). There are no numerical claims to audit in this section.

---

**SUMMARY**

All three quantitative claims in the Executive Summary are **SUPPORTED** by the source data. The Outlook section contains no quantitative or specifically enumerable forward-looking claims requiring verification.
